Skip to main content
SpringerLink
Log in

Tamoxifen and fluoxymesterone versus tamoxifen and danazol in metastatic breast cancer — A randomized study

  • Report
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Summary

A prospective randomized trial of tamoxifen and fluoxymesterone versus tamoxifen and danazol in metastatic breast cancer was conducted from December 1980 to September 1985. Patients were eligible regardless of site of disease, estrogen receptor status, or age. Sixty-two of sixty-three randomized patients were evaluable for response. Overall response for tamoxifen and fluoxymesterone was 11% with 61% stabilization of disease, versus 12% response rate for tamoxifen and danazol with 59% stabilization. Toxicities with tamoxifen and fluoxymesterone were greater with an increase in masculinization. We conclude that the response rates to the combinations of tamoxifen and fluoxymesterone or tamoxifen and danazol reported are equivalent in this study but that the increased toxicity with tamoxifen and fluoxymesterone would make tamoxifen and danazol the treatment of choice if a combination were to be used.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Mouridsen HT, Palshof R, Patterson J, Battersby L: Tamoxifen in advanced breast cancer. Cancer Treat Rev 5: 131–141, 1978

    PubMed  Google Scholar 

  2. Patterson JS, Battersby LA, Edwards DG: Review of the clinical pharmacology and international experience in advanced breast cancer. Reviews on Endocrine-Related Cancer 9: 563–582, 1981

    Google Scholar 

  3. Westerberg H: Tamoxifen and fluoxymesterone in advanced cancer: a controlled clinical trial. Cancer Treat Rep 64: 117–121, 1980

    PubMed  Google Scholar 

  4. Cooperative study. Testosterone propionate therapy in breast cancer. JAMA 188: 1069–1072, 1964

    Google Scholar 

  5. Allegra JC, Lippman ME, Thompson Bet al.: Distribution, frequency, and quantitative analysis of estrogen, progesterone, androgen, and glucocorticoid receptors in human breast cancer. Cancer Res 39: 1447–1454, 1979

    PubMed  Google Scholar 

  6. Potts GO: Pharmacology of danazol. J Int Med Res 5 (Supp 3): 1–14, 1977

    Google Scholar 

  7. Madanes AE, Farber M: Danazol. Ann Intern Med 96: 625–630, 1982

    PubMed  Google Scholar 

  8. Coombes RC, Perez D, Gazet JCet al.: Danazol treatment for advanced breast cancer. Cancer Chemother Pharmacol 10: 194–195, 1983

    PubMed  Google Scholar 

  9. Tormey DC, Lippman ME, Edwards BK, Cassidy JG: Evaluation of tamoxifen doses with and without fluoxymesterone in advanced breast cancer. Ann Int Med 98: 139–144, 1983

    PubMed  Google Scholar 

  10. McGuire WL, DeLaGarza M: Improved sensitivity in the measurement of estrogen receptor in human breast cancer. J Clin Endocrinol Metab 36: 548–552, 1973

    PubMed  Google Scholar 

  11. U.S. Department of Health, Education, and Welfare, Public Health Service, National Institutes of Health: Breast Cancer: Suggested protocol guidelines for combination chemotherapy trials and for combined modality trials. Publication No.(NIH) 78-1192, 1978

  12. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53: 457–481, 1958

    Google Scholar 

  13. Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemo Rep 50: 163–170, 1966

    Google Scholar 

  14. Gockerman JP, Spremulli EN, Raney M, Logan T: Randomized comparison of tamoxifen versus diethylstilbestrol in estrogen receptor positive or unknown metastatic breast cancer: a Southwestern Cancer Study Group Trial. Cancer Treat Rep 70: 1199–1203, 1986

    PubMed  Google Scholar 

  15. Henderson IC: Endocrine therapy in metastatic breast cancer.In: Harris JR, Hellman S, Henderson IC, Kinne DW (eds) Breast Diseases. J.B. Lippincott, London, 1987, pp. 398–428

    Google Scholar 

  16. Powles TJ, Gordon C, Coombes RC: Clinical trial of multiple endocrine therapy for metastatic and locally advanced breast cancer with tamoxifen-aminoglutethimide-danazol compared to tamoxifen used alone. Cancer Res (Suppl) 42: 3458–3460, 1982

    Google Scholar 

  17. Ingle JN, Green SJ, Ahmann DLet al: Randomized trial of tamoxifen alone or combined with aminoglutethimide and hydrocortisone in women with metastatic breast cancer. J Clin Oncol 4: 958–964, 1986

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medicine Branch, National Cancer Institute, Bethesda, Maryland, USA

    Sandra M. Swain, Caroline Bagley & Marc E. Lippman

  2. Biostatistics & Data Management Section, National Cancer Institute, Bethesda, Maryland, USA

    Seth M. Steinberg

Authors
  1. Sandra M. Swain
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Seth M. Steinberg
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Caroline Bagley
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Marc E. Lippman
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Swain, S.M., Steinberg, S.M., Bagley, C. et al. Tamoxifen and fluoxymesterone versus tamoxifen and danazol in metastatic breast cancer — A randomized study. Breast Cancer Res Tr 12, 51–57 (1988). https://doi.org/10.1007/BF01805740

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01805740

Key words

Search

Navigation